Along with CD19 CAR-T cells, other CAR-T cells directed against CD5, CD33, CD70, CD123, CD38, and B cell maturation antigen (BCMA) are under evaluation for hematological malignancies (HM) [24,25]. The gene discussed is TNFRSF17; the disease is hematologic disorder.